Zurich Cantonal Bank
CRNX icon

Zurich Cantonal Bank’s Crinetics Pharmaceuticals CRNX Stock Holding History

Zurich Cantonal Bank’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,116
Closed -$936K – 2807
2025
Q4 		$936K Buy
+20,116
New +$896K ﹤0.01% 1386

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Zurich Cantonal Bank's CRNX Position: Q1 2026 in Review

Zurich Cantonal Bank opened a new position in Crinetics Pharmaceuticals (CRNX) in Q1 2026: 26,439 shares worth $960K. The stake represents ﹤0.01% of the portfolio and ranks #1460 among its holdings. This is a return to the name: Zurich Cantonal Bank previously reported a position in CRNX as recently as Q3 2025.

Zurich Cantonal Bank first reported a position in CRNX in Q4 2021 and has held it in 17 quarters since. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Zurich Cantonal Bank held 26,439 shares of Crinetics Pharmaceuticals worth $960K as of Q1 2026.
  • Crinetics Pharmaceuticals was a new Zurich Cantonal Bank position in Q1 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #1460 holding.
  • Zurich Cantonal Bank first reported a position in Crinetics Pharmaceuticals in Q4 2021 and has held it in 17 quarters since.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.